FDA Clearance Tracker · P210005-S010
IC-8 Apthera Intraocular Lens (IOL)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 14, 2026
Approved
Time to decision
431 days
Received May 9, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P210005-S010
- Device name
- IC-8 Apthera Intraocular Lens (IOL)
- Applicant
- Acu Focus, Inc.
- Applicant location
- Irvine, CA
- Received
- May 9, 2025
- Decided
- Jul 14, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P210005
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
approval for continuing to conduct the PAS2 study under the currently approved protocol, SAIL-101-PAS2 Protocol Version 3.2, as approved under P210005/S004
Source documents
Other decisions for Acu Focus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P210005 · Decided Jul 22, 2022 · 513 days after receipt
Device type: Extended depth of focus intraocular lens (POE) · Ophthalmology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.